Meg Elias

Ms. Elias has more than 20 years of experience in the pharmaceutical and biotech industries. Prior to joining Arcutis in 2019, she led the study management group within Clinical Operations at Kite Pharma, and served as the Clinical Operations lead on the pivotal Phase II study which resulted in US and EU market approval of Yescarta®. Previously, she worked in clinical operations at Amgen and GlaxoSmithKline. She started her career in clinical nursing, and practiced for 10 years before joining industry. She received her Bachelor of Science in Nursing at Cedar Crest College.